Elena Liew

Edmonton, AB, CA 
Edmonton, AB, CA 

Overview

Elena Liew practices practicing medicine in Edmonton, Canada.

Her clinical expertise encompasses Leukemia, Myelofibrosis, Acute Myeloid Leukemia (AML), and Chronic Myelogenous Leukemia (CML).

She is actively involved in clinical research, co-authoring 13 peer reviewed articles and participating in 4 clinical trials.

Gender

Female

Locations

Edmonton, AB, Canada
Other Locations
Toronto, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2026
Intervention Type: Drug
Study Drugs: CPI-0610 BET Small Molecule Inhibitor, Ruxolitinib
Study Phase: Phase 3
A Patient Preferences-Controlled Study of Allogeneic Hematopoietic Cell Transplantation Versus Best Available Non-Transplant Therapies in Patients With High-Risk Myelofibrosis (ALLO-BAT Study)
A Patient Preferences-Controlled Study of Allogeneic Hematopoietic Cell Transplantation Versus Best Available Non-Transplant Therapies in Patients With High-Risk Myelofibrosis (ALLO-BAT Study)
Enrollment Status: Active_not_recruiting
Publish Date: July 06, 2026
Intervention Type: Biological, Drug
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
Enrollment Status: Completed
Publish Date: June 04, 2026
Intervention Type: Drug
Study Drugs: CPI-0610, Rituximab
Study Phase: Phase 1/Phase 2
A Phase I Study of Volasertib Combined With Standard Induction Chemotherapy for Previously Untreated Patients With Acute Myeloid Leukemia (VIAC)
A Phase I Study of Volasertib Combined With Standard Induction Chemotherapy for Previously Untreated Patients With Acute Myeloid Leukemia (VIAC)
Enrollment Status: Withdrawn
Publish Date: April 05, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 3 Less Clinical Trials

13 Total Publications

Proposed Modifications to Prognostic Classification of AML Patients Treated With Intensive Chemotherapy Based on Recent Real-World Data.
Proposed Modifications to Prognostic Classification of AML Patients Treated With Intensive Chemotherapy Based on Recent Real-World Data.
Journal: Clinical lymphoma, myeloma & leukemia
Published: September 29, 2025

Frequently Asked Questions about Elena Liew

Is Elena Liew a top-rated expert for Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Elena Liew is classified as an Experienced expert for Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Elena Liew participate in research or clinical trials?

Yes. Elena Liew has published 13 articles and abstracts on conditions like Leukemia. You can view a list of Elena Liew's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Liew's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile